Pozzoli Alberto, Torre Tiziano, Pedrazzini Giovanni, Demertzis Stefanos, Ferrari Enrico
Division of Cardiac Surgery, Cardiocentro Ticino Institute, EOC Lugano, Lugano, Switzerland.
Division of Cardiology, Cardiocentro Ticino Institute, EOC Lugano, Lugano, Switzerland.
Front Cardiovasc Med. 2022 Oct 20;9:967473. doi: 10.3389/fcvm.2022.967473. eCollection 2022.
Mitral annular calcification (MAC) may represent a significant challenge for heart surgeons with an extremely high perioperative risk during mitral valve (MV) surgery. The risk is further increased when patients fail to be eligible for any percutaneous treatment, particularly because circumferential calcifications involving the anterior leaflet suggest a critical obstruction of the left ventricular outflow tract (LVOT).
The objective of this study was to evaluate residual mitral regurgitation (MR) after surgical mitral valve replacement using a Sapien 3 Ultra (Edwards Lifesciences, CA, USA) transcatheter aortic valve implantation (TAVI) prosthesis, reinforced with a pericardial skirt, in high-risk selected patients with severe MAC.
Since 2020, five high-risk patients (mean age 70 years; 63-76; four women) with severe mitral disease in the context of severe MAC (computed tomography-based mean MAC Score 8.2 ± 1.1) were operated on after we adopted this novel technique. The operations were performed under general anesthesia, using a transapical TAVI delivery system to position the Sapien 3 in the mitral position under direct vision. To reinforce and avoid paravalvular leakages, a pericardial skirt was previously sewn around the prosthesis, securing it to the annulus and perivalvular atrial surface.
Sapien 3 Ultra implantation was successful without residual MR in all five patients (mild paravalvular leak in one case). Four patients had a 29-mm valve implanted, while one had a 26-mm valve implanted. Predilatation of the native annulus was never performed. Perfusion and clamping times were 134 ± 53 mins and 108 ± 43 mins, respectively. The presence of the pericardial skirt reduced the risk of leakage between the prosthesis and the rigid calcium surface, with final mean and maximal gradients of the TAVI prosthesis of 4.1 and 10.8 mmHg, respectively. There were no left ventricular outflow tract obstructions (mean LVOT gradient of 8 ± 1 mmHg). All patients were discharged, and neither mortality nor prosthetic dysfunction, nor residual mitral regurgitation was recorded. During follow-up, the last patient treated (MAC Score 10, severe calcification of the mitro-aortic junction) returned to our attention with a significant recurrent jet originating from the anterolateral commissure, currently medically treated, given the prohibitive redo risk.
Direct open surgical implantation of the Sapien 3 valve can be safely done in patients with severe MAC in dedicated centers. Reinforcing the TAVI prosthesis by sewing a pericardial skirt led to satisfactory perioperative and early postoperative results, reducing paravalvular leakages. Complex anatomies have a CERTAIN risk of recurrence.
二尖瓣环钙化(MAC)对于心脏外科医生而言可能是一项重大挑战,在二尖瓣(MV)手术期间围手术期风险极高。当患者不符合任何经皮治疗条件时,风险会进一步增加,特别是因为涉及前叶的环形钙化提示左心室流出道(LVOT)严重梗阻。
本研究的目的是评估在高危的重度MAC选定患者中,使用经心包裙加固的Sapien 3 Ultra(美国(美国加利福尼亚州爱德华兹生命科学公司)经导管主动脉瓣植入术(TAVI)假体进行二尖瓣置换术后的残余二尖瓣反流(MR)情况。
自2020年以来,我们采用了这种新技术,对5例高危患者(平均年龄70岁;63 - 76岁;4名女性)进行了手术,这些患者在重度MAC(基于计算机断层扫描的平均MAC评分8.2±1.1)背景下患有严重二尖瓣疾病。手术在全身麻醉下进行,使用经心尖TAVI输送系统在直视下将Sapien 3放置在二尖瓣位置。为了加固并避免瓣周漏,预先在心包裙周围缝合假体,将其固定在瓣环和瓣周心房表面。
所有5例患者Sapien 3 Ultra植入均成功,无残余MR(1例有轻度瓣周漏)。4例患者植入29毫米瓣膜,1例植入26毫米瓣膜。未对天然瓣环进行预扩张。灌注时间和阻断时间分别为134±53分钟和108±43分钟。心包裙的存在降低了假体与坚硬钙表面之间漏血的风险,TAVI假体的最终平均梯度和最大梯度分别为4.1和10.8 mmHg。无左心室流出道梗阻(平均LVOT梯度为8±1 mmHg)。所有患者均已出院,未记录到死亡、人工瓣膜功能障碍或残余二尖瓣反流。在随访期间,最后一名接受治疗的患者(MAC评分10,二尖瓣 - 主动脉交界处严重钙化)因源自前外侧连合处的大量复发性喷射反流再次引起我们的关注,鉴于再次手术风险过高,目前进行药物治疗。
在专门的中心,对于重度MAC患者可以安全地直接进行Sapien 3瓣膜的开放手术植入。通过缝合心包裙加固TAVI假体可带来令人满意的围手术期和术后早期结果,减少瓣周漏。复杂的解剖结构有一定的复发风险。